Circulating β (1-3) Glucan and Immunoglobulin G Subclass Antibodies toCandida albicansCell Wall Antigens in Patients with Systemic Candidiasis

Open Access
Publisher Website
Google Scholar
Abstract
Invasive candidiasis in patients who are immunocompromised or in intensive care units (ICUs) presents both diagnostic and therapeutic problems. We previously described antibodies that were directed against Candida albicans cell wall fragments (CW), periodate-treated CW (CWIO4), phosphopeptidomannan (PPM), and β(1-3) glucan. In this study, circulating fungal antigens [mannan and β(1-3) glucan] and immunoglobulin G (IgG) subclass antibodies to these cell wall antigens (anti-CW) were analyzed in patients with systemic candidiasis. Sera were collected from 14 patients on two or three consecutive occasions, starting on the day when candidiasis was culture proven. The sera were analyzed by enzyme-linked immunosorbent assay. The control groups consisted of lactating mothers (n = 9) (group I) who had breast milk that was positive for C. albicans and also had acute inflammation of the nipples, and age-matched blood donors (n = 10) (group II). Within the first 3 weeks of Candida infection all of the patients were positive for β(1-3) glucan by the Gluspecy test, but no patients were positive for mannan in the less-sensitive Pastorex Candida test. The controls were negative for both β(1-3) glucan (P = 0.019). The IgG2 levels of anti-CWIO4 and antiglucan antibodies correlated strongly (r = 0.681; P < 0.0001), and the absence of these antibodies was associated with increased levels of β(1-3) glucan. Increased levels of IgG1 anti-CW or IgG2 anti-PPM antibodies (titer of ≥3 logs) or of a combination of the two antibodies (log sum, ≥5) showed 92% sensitivity, 100% specificity, and positive predictive values. In conclusion, β(1-3) glucan and the two subclass antibodies appear to be early specific markers for the laboratory diagnosis of candidiasis. Furthermore, the kinetics of β(1-3) glucan appearance in serum may assist in evaluating the therapeutic efficacy of antifungal treatments.